Abfero Pharmaceuticals, Inc.

LEXINGTON, MA · Founded 2016 · CIK 0001769029 · Biotech · Acquired

Oral iron chelator molecules for treating iron overload diseases

abferopharmaceuticals.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$1.5M
3 Form D · Mar 2021
67 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$300,000
Private capital raisedForm D · SEC$680,000
Private capital raisedForm D · SEC$500,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1765Phaeno Inc——
1766Akeso Biomedical, Inc.—$2.1M
1767SegueTX-Pancreatic Cancer, L.L.C.——
1768Abfero Pharmaceuticals, Inc.—$1.5M
1769CARTHRONIX, INC.——
1770OPSIDIO, LLC—$800K
1771Bedrocan Internatioinal, Inc.—$200K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Steven BurkeDirector · Executive Officer
  • Thomas NeenanDirector · Executive Officer
  • Michael PeningtonDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.